Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lux

Showing results (161-170 of 233) with videos related to

Pageof 24
Sort By:
Geburtshilfe Und Frauenheilkunde|December 23, 2017
Update Breast Cancer 2017 - Implementation of Novel TherapiesMichael P Lux, Wolfgang Janni, Andreas D Hartkopf, et al.
BMC Cancer|February 7, 2014
FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patientsPeter A Fasching, Sebastian M Jud, Maik Hauschild, et al.
Oncotarget|November 5, 2017
Clinical validation of genetic variants associated with <i>in vitro</i> chemotherapy-related lymphoblastoid cell toxicityPeter A Fasching, Lothar Häberle, Brigitte Rack, et al.
Geburtshilfe Und Frauenheilkunde|February 16, 2022
Update Breast Cancer 2021 Part 5 - Advanced Breast CancerDiana Lüftner, Florian Schütz, Elmar Stickeler, et al.
Archives of Gynecology and Obstetrics|March 24, 2017
Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study networkCarlo Fremd, Carolin C Hack, Andreas Schneeweiss, et al.
Geburtshilfe Und Frauenheilkunde|March 27, 2018
Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and BiomarkersFlorin-Andrei Taran, Andreas Schneeweiss, Michael P Lux, et al.
Geburtshilfe Und Frauenheilkunde|March 14, 2022
Correction: Update Breast Cancer 2021 Part 5 - Advanced Breast CancerDiana Lüftner, Florian Schütz, Elmar Stickeler, et al.
Biochemical Pharmacology|December 7, 2011
Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001Christian R Loehberg, Pamela L Strissel, Ralf Dittrich, et al.
Geburtshilfe Und Frauenheilkunde|March 27, 2018
Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and PreventionAndreas Schneeweiss, Michael P Lux, Wolfgang Janni, et al.
Geburtshilfe Und Frauenheilkunde|September 16, 2022
Axillary Staging after Neoadjuvant Chemotherapy for Initially Node-Positive Breast Carcinoma in Germany: Initial Data from the AXSANA studySteffi Hartmann, Thorsten Kühn, Michael Hauptmann, et al.
Pageof 24

Showing results (161-170 of 233) with videos related to

Sort By:
Pageof 24
Geburtshilfe Und Frauenheilkunde|December 23, 2017
Update Breast Cancer 2017 - Implementation of Novel TherapiesMichael P Lux, Wolfgang Janni, Andreas D Hartkopf, et al.
BMC Cancer|February 7, 2014
FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patientsPeter A Fasching, Sebastian M Jud, Maik Hauschild, et al.
Oncotarget|November 5, 2017
Clinical validation of genetic variants associated with <i>in vitro</i> chemotherapy-related lymphoblastoid cell toxicityPeter A Fasching, Lothar Häberle, Brigitte Rack, et al.
Geburtshilfe Und Frauenheilkunde|February 16, 2022
Update Breast Cancer 2021 Part 5 - Advanced Breast CancerDiana Lüftner, Florian Schütz, Elmar Stickeler, et al.
Archives of Gynecology and Obstetrics|March 24, 2017
Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study networkCarlo Fremd, Carolin C Hack, Andreas Schneeweiss, et al.
Geburtshilfe Und Frauenheilkunde|March 27, 2018
Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and BiomarkersFlorin-Andrei Taran, Andreas Schneeweiss, Michael P Lux, et al.
Geburtshilfe Und Frauenheilkunde|March 14, 2022
Correction: Update Breast Cancer 2021 Part 5 - Advanced Breast CancerDiana Lüftner, Florian Schütz, Elmar Stickeler, et al.
Biochemical Pharmacology|December 7, 2011
Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001Christian R Loehberg, Pamela L Strissel, Ralf Dittrich, et al.
Geburtshilfe Und Frauenheilkunde|March 27, 2018
Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and PreventionAndreas Schneeweiss, Michael P Lux, Wolfgang Janni, et al.
Geburtshilfe Und Frauenheilkunde|September 16, 2022
Axillary Staging after Neoadjuvant Chemotherapy for Initially Node-Positive Breast Carcinoma in Germany: Initial Data from the AXSANA studySteffi Hartmann, Thorsten Kühn, Michael Hauptmann, et al.
Pageof 24